Compassionate use of ritlecitinib offers hope for severe hair loss patients

This program provides early access to ritlecitinib for people with severe alopecia areata who have lost at least half of their scalp hair and have not responded to or cannot tolerate standard treatments. The goal is to offer a potential treatment option before the drug is fully approved. Participants must meet additional eligibility criteria.